Stay updated on Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.

Latest updates to the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page
- Check3 days agoChange DetectedA new site-wide notice has been added about the lapse in government funding and the NIH Clinical Center's operating status. The page revision has been updated from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check10 days agoChange DetectedThe page now shows a glossary toggle and includes updated Study Record Dates such as Results First Posted and Certification/Extension First Posted, along with a new Revision/Version label.SummaryDifference0.3%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedResults posted for PICCOLO (NCT05041257): the page now includes posted results and related details for the Phase 2, single-arm Mirvetuximab Soravtansine study in FRα-positive ovarian, peritoneal, and fallopian tube cancers. The locations list has been updated to 35 sites worldwide with corresponding names and IDs, and key identifiers (EudraCT 2021-003592-34) plus study start and completion dates are displayed.SummaryDifference9%

- Check46 days agoChange DetectedThe Locations section was expanded to include numerous US states and international sites (e.g., New South Wales, South Australia, Victoria, Ontario, Quebec, Madrid), while the HHS Vulnerability Disclosure link was removed.SummaryDifference2%

- Check60 days agoChange DetectedThe study record shows a status change from 'No Results Posted' to 'Results Submitted' for NCT05041257.SummaryDifference0.0%

- Check68 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2 on the page; no substantive study information or user-facing features are affected.SummaryDifference0.0%

Stay in the know with updates to Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.